- 1 The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy
- 2 and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis
- 3 Albertus Ari Adrianto¹
- 4 Ignatius Riwanto¹
- 5 Udadi Sadhana²
- 6 Dewi Kartikawati Paramita^{3, 4, 5}
- 7 Henry Setyawan⁶
- 8 Kevin Christian Tjandra⁷
- 9 Danendra Rakha Putra Respati⁷
- 10 Derren David Christian Homenta Rampengan⁸
- 11 Roy Novri Ramadhan⁹
- 12 Gastin Gabriel Jangkang¹⁰
- 13 Endang Mahati¹¹
- ¹Department of Digestive Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang,
- 15 Indonesia
- ²Department of Anatomical Pathology, Faculty of Medicine, Universitas Diopnegoro,
- 17 Semarang, Indonesia
- ³Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing,
- 19 Universitas Gadjah Mada, Yogyakarta, Indonesia
- ⁴Integrated Research Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas
- 21 Gadjah Mada, Yogyakarta, Indonesia;
- ⁵Study Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, Indonesia
- ⁶Department of Public Health, Faculty of Public Health, Universitas Diponegoro, Semarang,
- 24 Indonesia;
- ⁷Department of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
- ⁸Medical Program, Faculty of Medicine, Universitas Sam Ratulangi
- ⁹Medical Program, Faculty of Medicine, Universitas Airlanga
- 28 ¹⁰Medical Program, Faculty of Medicine, Universitas Lambung Mangkurat
- 29 ¹¹Department of Pharmacology and Therapeutic, Faculty of Medicine, Diponegoro University,
- 30 Semarang, Indonesia
- 31 *Correspondence: Albertus Ari Adrianto
- 32 NOTE: This greating reports new research that has not been retified by pae Seview and should not be used to goide clinical practice.

Tel +628122824838 33 Fax -34 Email: medpubdiponegoro@gmail.com 35 Abstract 36 **Background:** Colorectal cancer (CRC) ranks third globally in cancer-related mortality, with 37 rising incidence, particularly in Asia, projecting a 60% surge by 2030. Metastatic CRC 38 (mCRC) presents a significant challenge with a grim 5-year survival rate of 14%. Emerging 39 evidence suggests that tumors with DNA mismatch repair deficiency (dMMR) and high 40 microsatellite instability (MSI-H) respond well to immune checkpoint inhibitors (ICIs), 41 marking a paradigm shift in therapeutic approaches. This systematic review and meta-42 analysis aim to comprehensively assess Pembrolizumab, Nivolumab, and the combination of 43 Nivolumab and Ipilimumab in advanced CRC, considering their significant antitumor 44 efficacy in MSI-H/dMMR mCRC. 45 Methods: Following PRISMA guidelines and Cochrane Handbook standards, this study 46 covers 2014 to 2024, involving advanced CRC patients treated with ICIs. A comprehensive 47 literature search employed 12 independent authors across eight databases. Parameters such 48 49 as overall survival, progression-free survival, and objective response rate were extracted. The Cochrane Collaboration's Risk of Bias version 2 tool assessed risk. Statistical analysis 50 utilized mean difference and risk ratios with random-effect models due to anticipated 51 52 heterogeneity. Robustness was ensured through publication bias analysis and sensitivity meta-analysis. Linear regression explored associations in subgroup analysis. 53 **Results:** The meta-analysis evaluated ORR and OS across different immunotherapy 54 interventions. Nivolumab, Nivolumab+Ipilimumab, and Pembrolizumab exhibited varying 55

ORR and OS effect sizes with corresponding heterogeneity levels. Progression-free survival

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

(PFS) analysis also showed diverse effect sizes and heterogeneity levels across the three interventions. The study provides a comprehensive overview of response rates and survival outcomes for these immunotherapies in advanced CRC. **Conclusions:** The study concludes that combination immunotherapy, particularly Nivolumab and Ipilimumab, presents a promising avenue for advanced CRC treatment, showing superior efficacy. Pembrolizumab monotherapy also exhibited promise. While the study offers valuable insights, the identified heterogeneity emphasizes the need for additional research. Adverse effects were generally low, supporting the viability of the studied immunotherapies. The study acknowledges limitations and calls for ongoing investigation to refine and validate these findings, marking a pioneering effort in systematically comparing short-term and longterm effects of anti-CTLA-4 and anti-PD-1 therapies in CRC. Keywords: Colorectal Cancer Immunotherapy, PD-1 and CTLA-4 Combination, Nivolumab, Ipilimumab, Pembrolizumab Efficacy and Safety Profiles Introduction Colorectal cancer (CRC) ranks as the third most common cause of cancer-related mortality globally[1]. Over the past thirty years, the incidence of CRC has surged in many nations, particularly in Asia, where a notable rise has been observed[2]. Projections indicate a significant rise in its worldwide incidence, with an expected increase of 60% by the year 2030 [1,3]. The prognosis remains poor for individuals diagnosed with metastatic colorectal cancer (mCRC), as evidenced by a 5-year survival rate of only 14%[4]. The incidence of CRC and its associated mortality rate rise with advancing age, with a median age of diagnosis typically reported as 68 years old. A striking 93% of CRC-related deaths are observed in individuals

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

aged 50 years and older. The relative survival rates at 5 and 10 years post-diagnosis for CRC stand at 65% and 58%, respectively[5]. Until recently, the treatment choices available for individuals with inoperable colorectal cancer worldwide have been predominantly confined to chemotherapy and targeted therapies[6]. Findings from several clinical trials indicate that CRC tumors identified by DNA mismatch repair deficiency (dMMR) and a high level of microsatellite instability (MSI-H) exhibit susceptibility to treatment with immune checkpoint inhibitors (ICIs)[7-9]. Tumors characterized as MSI-H/dMMR possess an elevated tumor mutational burden, leading to the generation of neoantigens, thereby rendering MSI-H/dMMR tumors more immunogenic compared to those with proficient DNA mismatch repair mechanisms. Consequently, MSI-H/dMMR tumors tend to harbor increased numbers of tumor-infiltrating lymphocytes, whose function can be potentiated by ICI therapy. Patients with MSI-H/dMMR mCRC typically derive less benefit from standard chemotherapy compared to those with microsatellite stable/mismatch repair-proficient mCRC[10,11]. However, MSI-H/dMMR status serves as a predictive indicator of favorable response to anti-programmed death (PD)-1 checkpoint inhibitor therapy [8,12,13] The interaction involving the PD-1 receptor and its ligands, PD-L1 and PD-L2, typically serves as an immune checkpoint mechanism responsible for regulating the equilibrium between Tcell activation, immune tolerance, and preventing immune-related tissue damage. This pathway is often exploited by tumors to evade immune surveillance[14]. PD-1 is present on T, B, and natural killer T cells, as well as activated monocytes and a significant portion of tumorinfiltrating lymphocytes (TILs) in various malignancies[14]. When PD-L1 (found on cells of diverse lineages) or PD-L2 (present on macrophages and dendritic cells) binds to the PD-1

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

receptor, it ultimately leads to the inhibition of T-cell function. Both PD-1 ligands have the potential to be expressed either constitutively or induced in various cell types, which also includes tumor cells[14]. Pembrolizumab is a selective humanized monoclonal antibody of the immunoglobulin G4/κ type, designed to specifically hinder the interaction between PD-1 and PD-L1/PD-L2 by directly binding to PD-1[15]. Previous studies have shown that checkpoint inhibitors targeting PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), including nivolumab and ipilimumab, respectively, synergize and stimulate an immune response against tumors through separate but complementary mechanisms. Nivolumab, a human monoclonal antibody blocking PD-1, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for use either alone or in combination with low-dose ipilimumab in patients diagnosed with MSI-H or dMMR mCRC. Another findings also reported that both pembrolizumab and nivolumab, inhibitors targeting PD-1, have demonstrated significant antitumor efficacy in patients with previously treated MSI-H/dMMR metastatic CRC[7–9]. Due to their distinct mechanism of action, immune checkpoint inhibitors are linked to adverse events (AEs) that contrast with those typically associated with chemotherapy. These immunerelated AEs commonly impact various bodily systems including the skin, gastrointestinal (GI) tract, lungs, kidneys, endocrine glands, and liver. Timely detection and appropriate management of these AEs, which may involve the use of systemic corticosteroids as necessary, could enhance outcomes for patients undergoing checkpoint inhibitor therapy (Brahmer et al., 2018). Understanding the predictors of response and resistance to immunotherapy is crucial for identifying patients who are most likely to benefit from these agents. Pembrolizumab, Nivolumab, and Ipilimumab represent novel therapeutic options for patients with advanced colorectal cancer, offering the potential for durable responses and improved survival outcomes. Therefore, this systematic review and meta-analysis aims to provide a comprehensive overview

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

of the efficacy and safety profiles of Pembrolizumab, Nivolumab, and Ipilimumab in advanced colorectal cancer, with insights into future directions and challenges in the immunotherapy landscape. **Material and Method** Registration The systematic review and meta-analysis titled "The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis" was officially registered on the Prospero on 24 February 2024 with registration number: CRD42024512511 Eligibility criteria This review adhered to the guidelines stipulated by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and the Cochrane Handbook[16,17]. The inclusion criteria encompassed studies involving patients of any age diagnosed with advanced or metastatic colorectal cancer, regardless of microsatellite instability-high and/or mismatch repair-deficient (MSI-H/ dMMR) status, treated by Pembrolizumab, Ipilimumab, and Nivolumab as the monotherapy or combination therapy. The primary focus was assessing the efficacy and safety of this treatment. The criteria for inclusion necessitated the availability of data on the mentioned primary outcomes published from 2014 until 2024. Furthermore, the eligible studies were restricted to observational designs (cohort/case-control) or randomized clinical trials (RCTs) or clinical trial.

The exclusion criteria were technical reports, editor responses, narrative reviews, systematic reviews, meta-analyses, non-comparative research, in silico studies, in vitro studies, in vivo studies, scientific posters, study protocoals, and conference abstracts. For data synthesis, the study will be grouped based on relevant comparators that include the use of Nivolumab+Ipilimumab, Nivolumab, and Pembrolizumab monotherapy.

Literature Search and Study Selection

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

A comprehensive search of English literature across eight international databases— Scopus, PubMed, Cochrane Library, Sage pub, ProQuest, Science Direct, Research Gate, Epistemonikos—was conducted by a team of 12 independent authors from inception until February 1st, 2024. To capture all potentially relevant literature, a combination of keywords was utilized, employed the following keywords: "Pembrolizumab" or "Nivolumab" or "Ipilimumab" and "colorectal carcinoma" and "therapeutic". The studies were organized and managed using the Mendeley Group Reference Manager in the authors' library. Initially, duplicate articles were removed, followed by screening based on titles and abstracts. Each researchers independently reviewed the titles and abstracts, resolving any disparities through discussion until reaching an agreement. Subsequently, they collaborated in 6 pairs of group to review the titles and abstracts of all retrieved articles. If necessary, the corresponding author was involved to make the final decision. Articles that passed this initial screening underwent full-text evaluation against predetermined inclusion/exclusion criteria. The full-text screening was conducted by the same 12 independent researchers with any discrepancies resolved through discussion with the corresponding author as the final decision maker.

Table 1. Keyword Used in Literature Searching

| Database | Keywords |
|------------------|--|
| Scopus | "Pembrolizumab" or "Nivolumab" or "Ipilimumab" and "colorectal |
| PubMed | carcinoma" and "therapeutic" |
| Cochrane Library | |
| Sage pub | |
| ProQuest | |
| Science Direct | |
| Research Gate | |
| Epistemonikos | |

Data Extraction

The following data were extracted for analytical purposes: study ID, publication year, country, study design, sample size, baseline characteristics of participants (mean age and sex distribution), follow-up duration, the number of participants in the buried and exposed K-wire groups, and the outcomes of interest. These data, extracted by 12 independent authors, were tabulated using Microsoft Excel 2019. The primary outcome assessment of efficacy incorporated into two general parameters, survival and therapy response. The survival parameter is indicated as overall survival (OS), progression-free survival (PFS) (The duration spanning both the treatment period and the subsequent phase following the intervention for a medical condition, such as cancer, wherein a patient sustains a state in which the disease neither progresses nor deteriorates). Furthermore, the response evaluation was assessed by objective

response rate (ORR) These parameters were chosen to holistically evaluate the influence of the therapeutic intervention among individuals afflicted with colorectal cancer. The adverse effect occured during the treatment indicated as our secondary outcomes.

Risk of Bias Assessment

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

The evaluation of bias risk was carried out by five independent authors utilizing validated instruments. To assess the quality of the included Randomized Controlled Trials (RCTs), the Cochrane Collaboration's Risk of Bias version 2 (RoB v2) tool was employed, comprising methodological assessments across five domains: (a) randomization process; (b) deviations from intended interventions; (c) missing outcome data; (d) measurement of the outcome; and (e) selection of the reported results. The outcomes are depicted in Fig 2. The authors' appraisals were categorized as "low risk," "high risk," or "some concerns" of bias. Two review authors (KCT, DR) independently utilized the tool for each included study and documented supporting information for their assessments of risk of bias in each domain. In evaluating the quality of included cohort/case-control studies or non randomized clinical trial, the Risk Of Bias In Nonrandomised Studies - of Interventions (ROBINS-I) was utilized, covering seven domains: (1) confounding; (2) selection of participants; (3) classification of intervention; (4) deviation from intended intervention; (5) missing data; (6) measurement of outcomes; (7) selection of the reported result. The authors' appraisals were categorized as "low risk," "high risk," or "some concerns" of bias. Two review authors (KCT, DR) independently utilized the tool for each included study and documented supporting information for their assessments of risk of bias in each domain. Any disparities in risk of bias assessments or justifications were addressed through discussion to achieve consensus between the two review authors (KCT, DR) If needed, corresponding author (EM) served as an arbiter to facilitate resolution

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

Statistical Analysis For the analytical synthesis of continuous variable outcomes, we employed the mean difference (SMD) with 95% confidence intervals (95% CI), utilizing the Inverse-Variance formula. Dichotomous variable outcomes were pooled into risk ratios (RR) with 95% CI using the Mantel-Haenszel formula. Given the anticipated substantial heterogeneity due to variations in population characteristics and follow-up durations, random-effect models were selected for this review. Heterogeneity between studies was assessed using the I-squared (I2) statistic, where values exceeding 50% were categorized as significant heterogeneity. To facilitate pooled analysis, we employed a combined formula from Luo D et al.[15] and Wan X et al.[16] for transforming data expressed as the median and interquartile range (IQR), or median, minimum, and maximum into mean and standard deviations (SD). Reporting bias and Certainity assessment Publication bias analysis was conducted when there were more than 10 studies for each outcome of interest. In cases of funnel plot asymmetry, a thorough examination of characteristics aimed to discern whether observed asymmetry could be attributed to publication bias or other factors like methodological heterogeneity among studies. All statistical analyses were executed using JAMOVI 2.3. The robustness of outcomes was scrutinized through sensitivity meta-analysis, exclusively considering studies with an overall low risk of bias. In the subgroup analysis, a commonly employed statistical methodology for data analysis involves elucidating associations between a dependent variable and one or more independent variables. Utilizing linear regression, the model centers on the dependent variable (e.g., sample size, age, sex, and follow-up duration), evaluating whether these variables influence the

observed associations. The selection of variables is guided by theoretical considerations and

their relevance to analytical objectives. JAMOVI 2.3 was employed for conducting subgroup analysis, ensuring robust data interpretation.

Result

Study Selection and Characteristics

A comprehensive literature search across eight international databases identified a total of 27,974 studies. Then the filter of released date and type of article were performed, 15,955 articles were automatically removed before being included into screening process. After the elimination of duplicate entries and initial screening based on titles and abstracts, 11,519 studies were removed due to irrelevant topics and 458 studies were removed due to non-RCT and non-clinical trial studies, resulting in a final selection of 42 studies. Subsequently, a thorough evaluation of these 42 studies in full-text format revealed that 24 studies did not meet the desired outcomes and 5 studies were not retrievable. Consequently, only 13 studies satisfied the eligibility criteria and were included in the final analysis, as illustrated in Figure 1. Sample sizes ranged from 11 to 307, with follow-up durations varying from 5.3 month to 44.5 month. A comprehensive overview of the baseline characteristics of the included studies is presented in Table 2.

| No | Title | Author | Country | Study | | Population | | | | | | | | |
|----|--|---------------------------|--|------------|-----------------|--------------|----------------|----------------|------------------------------------|--------------|--------------------------|----------|---------------|---|
| • | | ;Year | /Place | Desig n | Sample size (n) | Mal e (n) | Femal e (n) | Age (years) | Interve n-tion | Con t-rol | Interve n-tion (n) | Cont-rol | Follow- up | Dosage |
| 1 | Safety of Nivolumab plus Low- Dose Ipilimumab in Previously Treated Microsatelli te Instability- High/Mism atch Repair- Deficient Metastatic Colorectal Cancer[18] | Morse, et al; 2019 | USA | Cohor t | 119 | Nr | Nr | Nr | Nivolu m-ab + Ipilimu mab | Nill | 119 | Nill | 13.4 months | Nivolumab 3 mg/kg plus 1 mg/kg ipilimumab Q3W followed by nivolumab 3 mg/kg Q2W |
| 2 | Safety and antitumor activity of the anti–PD-1 antibody pembrolizu mab in | O'Neil, et al; 2017 | Canada, France, Italy, the Republic of Korea, Spain, the | Cohor | 23 | 13 | 10 | 57 (40– 78) | Pembro l- izumab | Nill | 23 | Nill | 5.3 months | 10 mg/kg |

| | patients with advanced colorectal carcinoma[1 9] | | United Kingdo m, and the United States | | | | | | | | | | | |
|---|--|------------------------|---|---|----|----|----|-------------------------|-------------------------------------|------|----|------|-------------|--|
| 3 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizu mab in patients with recurrent carcinoma of the anal canal [20] | Ott, et al; 2017 | Europe and the USA | Cohor | 25 | 2 | 23 | 63 (46– 82 | Pembro I- izumab | Nill | 25 | Nill | 10.6 months | 10 mg/kg |
| 4 | RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with | Cohen, et al; 2020 | Nr | Non- rando mized Clinic al Trial | 57 | 30 | 27 | 56.5 (45.8– 63.8) | Nivolu m-ab + Ipilimu m-ab | Nill | 57 | Nill | 18.1 months | 3 mg/kg intravenously and ipilimumab 1 mg/kg intravenously |

| 5 | microsatellit e instability- high/mismat ch repairdeficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study[21] Phase II | Okuma | Japan | Non- | 11 | 3 | 8 | 70 (54– | Nivolu | Nill | 11 | | 24.7 | 240 mg/kg |
|---|--|-------------------------|-------|---|-----|-----|-----|---------------------|------------------------|------------|-----|-----|-------------|-----------|
| | Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)[22] | , et al; 2023 | | rando mized Clinic al Trial | | | | 78) | m-ab | | | | months | |
| 6 | Pembrolizu mab versus chemothera | Diaz, et al; 2022 | Japan | Rand omize d | 307 | 153 | 154 | 62.5 (24– 93) | Pembro 1- izumab | che mot | 153 | 154 | 44.5 months | 200 mg/kg |

| | py for | | | Clinic | | | | | | hera | | | | |
|---|---------------|-----------|----------|--------|-----|-----|-----|---------|--------|------|-----|-----|--------|-----------|
| | microsatellit | | | | | | | | | | | | | |
| | | | | al | | | | | | py | | | | |
| | e 1 :1:4 | | | Trial | | | | | | | | | | |
| | instability- | | | | | | | | | | | | | |
| | high or | | | | | | | | | | | | | |
| | mismatch | | | | | | | | | | | | | |
| | repair- | | | | | | | | | | | | | |
| | deficient | | | | | | | | | | | | | |
| | metastatic | | | | | | | | | | | | | |
| | colorectal | | | | | | | | | | | | | |
| | cancer | | | | | | | | | | | | | |
| | (KEYNOTE | | | | | | | | | | | | | |
| | -177): final | | | | | | | | | | | | | |
| | analysis of a | | | | | | | | | | | | | |
| | randomised, | | | | | | | | | | | | | |
| | open-label, | | | | | | | | | | | | | |
| | phase 3 | | | | | | | | | | | | | |
| | study[23] | | | | | | | | | | | | | |
| 7 | Pembrolizu | André, | USA | Rand | 307 | 153 | 154 | 63.0 | Pembro | che | 153 | 154 | 32.4 | 200 mg/kg |
| | mab in | et al; | | omize | | | | (24– | 1- | mot | | | months | |
| | Microsatelli | 2020 | | d | | | | 93) | izumab | hera | | | | |
| | te- | | | Clinic | | | | | | py | | | | |
| | Instability- | | | al | | | | | | | | | | |
| | High | | | Trial | | | | | | | | | | |
| | Advanced | | | | | | | | | | | | | |
| | Colorectal | | | | | | | | | | | | | |
| | Cancer[24] | | | | | | | | | | | | | |
| 8 | Pembrolizu | Yoshin | Japan, | Rand | 48 | 23 | 25 | 64 (24– | Pembro | che | 22 | 26 | 45.3 | 200 mg/kg |
| | mab in | o, et al; | Korea, | omize | | | | 83) | 1- | mot | | | (range | |
| | Asian | 2022 | Singapor | d | | | | | izumab | hera | | | 38.1– | |
| | patients | | e, and | Clinic | | | | | | ру | | | 57.8) | |
| | with | | Taiwan | | | | | | | | | | months | |

| | microsatellit e- instability- high/mismat ch-repair- deficient colorectal cancer[24] | | | al Trial | | | | | | | | | | |
|----|--|--------------------------------|-------------|---|----|----|----|-------------------------|------------------------|------|----|------|-------------|----------|
| 9 | PD-1 Blockade in Tumors with Mismatch- Repair Deficiency[7] | Le, et al; 2015 | Nr | Cohor | 41 | 24 | 17 | 46 (24– 65) | Pembro l- izumab | Nill | 41 | Nill | 36 weeks | 10 mg/kg |
| 10 | Nivolumab in patients with metastatic DNA mismatch repair deficient/mi crosatellite instability— high colorectal cancer (CheckMate 142): results of an open- | Overm an, et al; 2017 | 8 countries | Non- rando mized Clinic al Trial | 74 | 44 | 30 | 52·5 (44·0– 64·0) | Nivolu m-ab | Nill | 74 | Nill | 12·0 months | 3 mg/kg |

| | label, multicentre, phase 2 study[8] | | | | | | | | | | | | | |
|----|---|-------------------------|-------------|---|----|----|----|----------------|-------------------------------------|------|----|------|-------------|---|
| 11 | Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study[25] | Morris, et al; 2017 | USA | Non- rando mized Clinic al Trial | 37 | 10 | 27 | 56 (51– 64) | Nivolu m-ab | Nill | 37 | Nill | 10.1 months | 3 mg/kg |
| 12 | First-Line Nivolumab Plus Low- Dose Ipilimumab for Microsatelli te Instability- High/ Mismatch Repair- Deficient | Lenz, et al; 2021 | 6 countries | Cohor | 45 | 23 | 22 | 66 (21- 85) | Nivolu m-ab + Ipilimu m-ab | Nill | 45 | Nill | 24.2 months | Nivolumab 3 mg/kg and low- dose ipilimumab 1 mg/kg |

| | Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study[26] | | | | | | | | | | | | | |
|----|--|--------------------------------|-----|-------|-----|----|----|----------------|-------------------------------------|------|-----|------|-------------|--|
| 13 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair— Deficient/M icrosatellite Instability— High Metastatic Colorectal Cancer[27] | Overm an, et al; 2018 | USA | Cohor | 119 | 70 | 49 | 58 (21- 88) | Nivolu m-ab + Ipilimu m-ab | Nill | 119 | Nill | 13.4 months | Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg |

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277278

279

Figure 1. PRISMA 2020 flow diagram. Risk of Bias in Studies Each clinical trial and randomized controlled trial underwent a rigorous evaluation employing the ROB-2 method. Among the identified studies, three exhibited a level of bias concern, primarily attributed to confounding, classification of interventions, missing data, and reported results. The visualization of the risk-of-bias assessment is presented in Figure 2. Figure 2. (A) ROBINS-I Risk of Bias Assessment; (B) ROB-2 Risk of Bias Assessment *Objective response rate (ORR)* Three studies that administered Nivolumab reported ORR with an effect size of 0.34 [95% CI **0.18**; -0.49, P<0.001]. Heterogeneity was found to be moderate and the funnel plot shows no evidence of heterogeneity. Figure 3. (A) Forest plot of ORR nivolumab intervention; (B) Funnel plot of ORR nivolumab intervention Four studies that administered Nivolumab and Ipilimumab reported ORR with an effect size of 0.53 [95% CI 0.42; -0.65, P<0.001]. Heterogeneity was found to be high and the funnel plot shows evidence true of heterogeneity. Figure 4. (A) Forest plot of ORR Nivolumab and Ipilimumab intervention; (B) Funnel plot of ORR Nivolumab and Ipilimumab intervention Six studies that administered Pembrolizumab reported ORR with an effect size of 0.34 [95%] CI 0.19; 0.48, P<0.001]. Heterogeneity was found to be high and the funnel plot shows evidence true of heterogeneity.

281

282

283

284

285

286

287

288

289

290

291292

293

294

295

296297

298

299

300

301

302

Figure 5. (A) Forest plot of ORR Pembrolizumab intervention; (B) Funnel plot of ORR Pembrolizumab intervention Overall Survival Three studies that administered Nivolumab reported OS with an effect size of 0.68 [95% CI 0.52; 0.84, P<0.001]. Heterogeneity was found to be moderate and the funnel plot shows no evidence true of heterogeneity. Figure 6. (A) Forest plot of OS Nivolumab intervention; (B) Funnel plot of OS Nivolumab intervention Four studies that administered Nivolumab and Ipilimumab reported OS with an effect size of 0.84 [95% CI 0.81; 0.88, P<0.001]. Heterogeneity was found to be absent and the funnel plot shows no evidence true of heterogeneity. Figure 7. (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of OS nivolumab and Ipilimumab intervention Five studies that administered Pembrolizumab reported OS with an effect size of 0.56 [95%] CI 0.37; 0.75, P<0.001]. Heterogeneity was found to be high and the funnel plot shows evidence true of heterogeneity. Figure 8. (A) Forest plot of OS Pembrolizumab intervention; (B) Funnel plot of OS Pembrolizumab intervention *Progression-free survival (PFS)*

304

305

306

307

308

309

310

311

312

313

314

315

316

317318

319

320

321

322

323

324

Three studies that administered Nivolumab reported PFS with an effect size of 0.53 [95% CI **0.43**; **0.64**, **P**<**0.001**]. Heterogeneity was found to be low and the funnel plot shows no evidence true of heterogeneity Figure 9. (A) Forest plot of PFS Nivolumab intervention; (B) Funnel plot of PFS Nivolumab intervention Four studies that administered Nivolumab and Ipilimumab reported PFS with an effect size of **0.72** [95% CI 0.67; 0.77, P<0.001]. Heterogeneity was found to be absent and the funnel plot shows no evidence true of heterogeneity. Figure 10. (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of OS Nivolumab and Ipilimumab intervention Five studies that administered Pembrolizumab reported PFS with an effect size of 0.53 [95%] CI 0.34; 0.72, P<0.001]. Heterogeneity was found to be high and the funnel plot shows evidence true of heterogeneity. Figure 11. (A) Forest plot of PFS Pembrolizumab intervention; (B) Funnel plot of PFS Pembrolizumab intervention The effect size of each subgroup is summarized in Table 3 below. **Table 3.** Size effects comparison of each subgroup **Objective Response Rate (ORR)**

| Intervention | Effect Size (95% CI) |
|------------------------|----------------------|
| Nivolumab | 0.34 (0.18; -0.49) |
| Nivolumab + Ipilimumab | 0.53 (0.42; -0.65) |
| Pembrolizumab | 0.34 (0.19; 0.48) |

325 Overall Survival (OS)

| Intervention | Effect Size (95% CI) |
|------------------------|----------------------|
| Nivolumab | 0.68 (0.52; 0.84) |
| Nivolumab + Ipilimumab | 0.84 (0.81; 0.88) |
| Pembrolizumab | 0.56 (0.37; 0.75) |

Progression-Free Survival (PFS)

| Intervention | Effect Size (95% CI) |
|------------------------|----------------------|
| Nivolumab | 0.53 (0.43; 0.64) |
| Nivolumab + Ipilimumab | 0.72 (0.67; 0.77) |
| Pembrolizumab | 0.53 (0.34; 0.72) |

Discussion

Immunotherapy stands as a pivotal cornerstone in tumor control, and the exploration of combination immunotherapy involving multiple agents has emerged as a promising strategy. This comprehensive approach strategically intervenes in diverse immune response processes, encompassing chemoradiotherapy, targeted therapy, and interactions with immune pathways. By orchestrating a multifaceted anti-tumor immune response, combination immunotherapy seeks to mitigate the risk of drug resistance, marking it as a highly promising avenue for investigation[28].

Among the various combinations being studied, the concurrent administration of anti-PD-1 (nivolumab and ipilimumab) and anti-CTLA-4 (ipilimumab) has exhibited notable efficacy in tumor treatment[29,30]. This combination has demonstrated positive outcomes and substantial improvements in patients with metastatic melanoma, advanced renal cell carcinoma (RCC), and metastatic colorectal cancer (CRC)[30]. Cope et al. reported superior response rates in recurrent small cell lung cancer (SCLC) when treated with nivolumab plus ipilimumab, surpassing conventional chemotherapy and suggesting potential long-term survival

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

presented in previous studies.

benefits[31]. Additionally, Ready et al. provided evidence supporting the effectiveness and tolerability of the combination of nivolumab and low-dose ipilimumab as a first-line treatment for advanced/metastatic non-small cell lung cancer (NSCLC)[32]. In the realm of combination immunotherapy, the inclusion of pembrolizumab has further broadened the horizon of treatment modalities. Pembrolizumab, an anti-PD-1 agent, has demonstrated its efficacy in various malignancies[33,34]. The concurrent use of pembrolizumab with nivolumab and ipilimumab has shown promising outcomes, particularly in advanced RCC. Shao's conditional survival analysis of first-line treatment highlighted that patients with advanced RCC undergoing pembrolizumab in combination with nivolumab and ipilimumab therapy exhibited a high survival rate compared to those receiving sunitinib[35]. This accumulating evidence underscores the potential synergistic effects of combining immunotherapeutic agents, notably anti-PD-1 and anti-CTLA-4, in conjunction with pembrolizumab, opening new avenues for the advancement of cancer treatment modalities. The primary objective of this investigation was to assess the effectiveness and safety of immunotherapy drugs in the context of colorectal cancer. A comprehensive analysis was conducted, incorporating data from a total of 13 studies, encompassing a sample size of 1337 patients. The assessment of Efficacy (ORR, OS, PFS) for each groups with the investigation of adverse events and survival can validate the safety of this immunotherapy. However, AEs will only be covered descriptively in this study due to the different ways in which they have been

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

The combination of nivolumab and ipilimumab demonstrates the highest efficacy, with an ORR of 0.53, OS of 0.84, and PFS of 0.72. Pembrolizumab monotherapy also shows promising results, with an ORR of 0.34, OS of 0.56, and PFS of 0.53. However, the heterogeneity observed in some of the outcomes highlights the need for further studies to confirm these findings. The combination of nivolumab and ipilimumab has been shown to be effective in various cancers, including colorectal carcinoma. The combination of these two medicine may enhance the immune response against cancer cells by targeting different checkpoints in the immune system. The high efficacy observed in our meta-analysis supports the use of this combination in mCRC patients[18]. Pembrolizumab, a PD-1 inhibitor, has been approved for the treatment of mCRC patients with dMMR or MSI-H tumors. The promising results observed in our meta-analysis suggest that pembrolizumab may be a viable treatment option for a broader range of mCRC patients. Further research is needed to confirm these findings and to explore the optimal treatment strategies for mCRC patients[19]. Ipilimumab+Nivolumab and Nivolumab monotherapy have been evaluated in earlier metaanalyses conducted across multiple publications with varying cancer types. It has been reported that the combination outperforms nivolumab monotherapy in terms of ORR and DCR, however patients may experience increased AEs[36]. One particular instance where using Ipilimumab+Nivolumab has been clearly demonstrated in multiple meta-analyses to result in improved ORR response[37–39]. Ipilimumab+Nivolumab use, however, still requires cautious consideration because of the possibility of excessive adverse effects. Therefore, more thorough research is required to determine how each type of cancer is affected by the combination of Ipilimumab and Nivolumab[40].

The Adverse Effects (AEs) found according to previous meta-analyses indicating a high incidence of AEs in the gastrointestinal system. However, in contrast, with the endocrine system, the use of anti-CTLA-4 or anti-PD-1 immunotherapy is reported to have a greater potential to cause endocrine issues (such as hypothyroidism, hyperthyroidism, thyroiditis, and adrenal insufficiency) in other cancers[41,42]. These findings are also in line with the study conducted by Almutairi AR, et al., 2020, who stated that Healthcare providers must remain vigilant in monitoring for immune-related adverse events (irAEs) subsequent to combined therapeutic interventions[43]. Additionally, particular attention should be directed towards gastrointestinal and cutaneous irAEs in the context of ipilimumab therapy. Furthermore, clinicians should be cognizant of the potential occurrence of irAEs associated with hyperglycemia, thyroid dysfunction, hepatic abnormalities, and musculoskeletal disorders following administration of nivolumab and pembrolizumab[43]. However, this treatment strategy is still preferable compared to conventional chemotherapy since it has better efficacy with the same adverse effects as stated by O'bryne K, et al., 2023. There was no statistically significant difference in the occurrence of adverse events (AEs) necessitating discontinuation between the combination of nivolumab and ipilimumab (NIVO + IPI) and pembrolizumab combined with chemotherapy, as well as between NIVO + IPI and pembrolizumab monotherapy. However, it is noteworthy that the incidence of treatment-related grade ≥3 AEs was higher with NIVO + IPI compared to pembrolizumab monotherapy[39].

Strength and limitation

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

To our knowledge, this study represents the first systematic review and meta-analysis that compares both short-term and long-term effects of presently available anti-CTLA-4 and anti-PD-1 combination or monotherapies for treating patients with CRC. The PICOS criteria

necessitated significant follow-up period in each trial to mitigate potential bias arising from heavily censored data in the tails of treatment arms during the observation period. Methodologically, the analysis was executed utilizing the meta library package in the Jamovi for the comprehensive analysis. The metabias package facilitated the execution of the Egger test, revealing evidence of heterogeneity for ORR, OS, and PFS outcomes. Additionally, the funnel plots also indicated evidence of heterogeneity for these outcomes. However, it is noteworthy that the prevalence of AEs, in general, remained at a low level, with instances of either absent or non-significant heterogeneity for certain AEs. However, this study does have some limitations. Due to variations in the presentation of adverse events (AEs) across studies, with one individual potentially experiencing two or more AEs simultaneously, extracting data posed challenges for us. Additionally, It can be quite challenging to classify an AE as a potential immune-related AE (irAE), as this determination may vary among trials or observers. This variability could introduce detection bias, particularly because our analysis included both open-label and double-blind trials. Such variations might result in an overestimation of the incidence of potential irAEs. Nevertheless, we made efforts to mitigate this by only including patients treated with either anti-CTLA-4 or anti-PD-1 monotherapies or combination therapies, thereby excluding AEs that could be attributed to other treatments or immunotherapies. Furthermore, we employed the random-effects model for the meta-analyses and conducted subgroup analyses to address high heterogeneity, aiming to accommodate potential variations in the outcomes observed across the included studies. Moreover, significant statistical heterogeneity observed in most analyses is a crucial consideration. Variations in study designs, tumor stage, prior treatment history, and other characteristic among the included studies could have contributed to this heterogeneity.

Conclusion

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

In conclusion, the exploration of combination immunotherapy involving anti-PD-1 and anti-CTLA-4 agents presents a promising avenue in cancer treatment, demonstrating notable efficacy across various cancers, including colorectal cancer (CRC). The concurrent use of nivolumab and ipilimumab, particularly, showcased superior efficacy in terms of objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). Pembrolizumab monotherapy also exhibited promising results, highlighting its efficacy in treating CRC. While the study, encompassing 13 studies with 1337 patients, provides valuable insights into the effectiveness and safety of immunotherapy in CRC, the identified heterogeneity in some outcomes emphasizes the necessity for additional research and exploration. Adverse effects, mainly observed in the gastrointestinal and endocrine systems, were generally low in incidence. Despite the higher incidence of treatment-related grade ≥3 adverse events with the nivolumab and ipilimumab combination, the superior efficacy observed supports its consideration as a viable treatment option. This study represents a pioneering systematic review comparing shortterm and long-term effects of anti-CTLA-4 and anti-PD-1 therapies in CRC, acknowledging certain limitations and the need for ongoing investigation to refine and validate these findings. Data availability

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

- Underlying data
- All data underlying the results are available as part of the article and no additional source 456
- data are required. 457
- Reporting guidelines 458

Mendeley Data doi: 10.17632/zhvz39sggy.1. 459 460 Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). 461 462 **Funding** 463 The author(s) declared no funding information available. 464 465 **Competing interests** 466 No competing interests were disclosed. 467 468 **Grant information** 469 The author(s) declared that no grants were involved in supporting this work. 470 471 Acknowledgment 472 We would like to express our sincere gratitude to the Indonesian Health Research Foundation 473 for their invaluable contribution in reviewing and enhancing the quality of this systematic 474 review and meta-analysis. Their expertise and insightful feedback have significantly enriched 475 the rigor and comprehensiveness of our research. We acknowledge the Foundation's 476 477 commitment to advancing healthcare research and their dedication to fostering excellence in scientific inquiry. This collaboration has been instrumental in shaping the robustness of our 478 study, and we extend our heartfelt appreciation for their support in promoting the advancement 479 480 of health knowledge.

Reference

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.
- Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, et al. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019 Dec 1;4(12):913–33.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–86.
- 493 4. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 6;67(3):177–93.
- American Cancer Society. Colorectal Cancer Screening* Prevalence (%) among Adults
 Age 50 Years and Older by State, 2012. 2014.
- 497 6. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-498 Asian adapted ESMO consensus guidelines for the management of patients with 499 metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, 500 MOS, SSO and TOS. Annals of Oncology. 2018 Jan 1;29(1):44–70.
- Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade
 in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine. 2015
 Jun 25;372(26):2509–20.
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep 1;18(9):1182–91.
- 508 9. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (1979). 2017 Jul 28;357(6349):409–13.
- Heinemann V KNBH et al. Somatic DNA mutations, tumor mutational burden (TMB), and MSI status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306). J Clin Oncol . 2018;36:3591a.
- Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clinical Cancer Research. 2014 Oct 15;20(20):5322–30.
- 518 12. Diaz LA MADJ et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol . 2017;35:3071a.

- 520 13. Marginean EC, Melosky B. Is there a role for programmed death ligand-1 testing and
- immunotherapy in colorectal cancer with microsatellite instability?: Part II-the
- challenge of programmed death ligand-1 testing and its role in microsatellite instability-
- high colorectal cancer. In: Archives of Pathology and Laboratory Medicine. College of
- American Pathologists; 2018. p. 26–34.
- 525 14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Vol. 12, Nature Reviews Cancer. 2012. p. 252–64.
- 527 15. O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety
- and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with
- advanced colorectal carcinoma. PLoS One. 2017 Dec 1;12(12).
- 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Vol.
- 532 372, The BMJ. BMJ Publishing Group; 2021.
- 533 17. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated
- guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for
- Systematic Reviews of Interventions. Vol. 10, The Cochrane database of systematic
- reviews. NLM (Medline); 2019. p. ED000142.
- 18. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, et al. Safety of
- Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-
- High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 Nov
- 540 1;24(11):1453–61.
- 541 19. O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety
- and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with
- advanced colorectal carcinoma. PLoS One. 2017 Dec 1;12(12).
- 544 20. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, et
- al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients
- with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036–41.
- 547 21. Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D,
- et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in
- patients with microsatellite instability-high/mismatch repair-deficient metastatic
- colorectal cancer: The GERCOR NIPICOL phase II study. J Immunother Cancer. 2020
- 551 Nov 3;8(2).
- 552 22. Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, et al.
- Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and
- Relation with Immune Phenotypic Analysis (the ROCK Trial). Clinical Cancer
- Sesent Ses
- 556 23. Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab
- versus chemotherapy for microsatellite instability-high or mismatch repair-deficient
- metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-
- label, phase 3 study. Lancet Oncol. 2022 May 1;23(5):659–70.

- Yoshino T, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, et al. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer. Cancer Sci. 2023 Mar 1;114(3):1026–36.
- Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Apr 1;18(4):446–53.
- Lenz HJ, Eric ;, Cutsem V, Limon ML, Yeung K, Wong M, et al. First-Line Nivolumab
 Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin
 Oncol [Internet]. 2021;40:161–70. Available from: https://doi.
- Overman MJ, Lonardi S, Yeung K, Wong M, Lenz HJ, Gelsomino F, et al. JOURNAL
 OF CLINICAL ONCOLOGY Durable Clinical Benefit With Nivolumab Plus
 Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High
 Metastatic Colorectal Cancer. J Clin Oncol [Internet]. 2018;36:773–9. Available from:
 https://doi.org/10.1200/JCO.2017.
- 575 28. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
- Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Vol. 62, International Immunopharmacology. Elsevier B.V.; 2018. p. 29–39.
- 580 30. Ghiringhelli F, Fumet JD. Is There a Place for Immunotherapy for Metastatic 581 Microsatellite Stable Colorectal Cancer? Vol. 10, Frontiers in immunology. NLM 582 (Medline); 2019. p. 1816.
- Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018 May 14;33(5):853-861.e4.
- Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al.
 Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell
 Lung Cancer: Results From the CheckMate 032 Randomized Cohort. Journal of
 Thoracic Oncology. 2020 Mar 1;15(3):426–35.
- 591 33. Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, et al. Immunotherapy in colorectal cancer: Current achievements and future perspective. Vol. 17, International Journal of Biological Sciences. Ivyspring International Publisher; 2021. p. 3837–49.
- Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase i study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clinical Cancer Research. 2015 Oct 1;21(19):4286–93.

- 598 35. Shao N, Wan F, Zhu Y, Ye D. Conditional survival in patients with advanced renal cell carcinoma treated with nivolumab. Medical Science Monitor. 2019 Aug 30;25:6518–600 22.
- 36. Xu Y, Hezam K, Ali MG, Wang Y, Zhang J. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. Vol. 43, Immunopharmacology and Immunotoxicology. Taylor and Francis Ltd.; 2021. p. 386–94.
- Ando K, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, et al. Nivolumab plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: A systematic review and network meta-analysis. Vol. 12, Cancers. MDPI AG; 2020. p. 1–19.
- Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, et al. Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and metaanalysis. Vol. 21, Cancer Cell International. BioMed Central Ltd; 2021.
- O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, et al. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. Lung Cancer. 2023 Mar 1;177:11–20.
- 616 40. Serritella A V., Shenoy NK. Nivolumab Plus Ipilimumab vs Nivolumab Alone in 617 Advanced Cancers Other Than Melanoma: A Meta-Analysis. JAMA Oncol. 2023 Oct 618 19;9(10):1441–6.
- Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety
 profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Vol. 13,
 Nature Reviews Clinical Oncology. Nature Publishing Group; 2016. p. 473–86.
- 622 42. El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Vol. 119, Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd; 2017. p. 1–12.
- Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related
 Adverse Events Associated With Monotherapy and Combination Therapy of
 Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic
 Review and Meta-Analysis. Vol. 10, Frontiers in Oncology. Frontiers Media S.A.; 2020.





Figure 1. PRISMA 2020 flow diagram








Figure 2. (A) ROBINS-I Risk of Bias Assessment



D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.

D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

- Some concerns
- Low






Figure 3. (A) Forest plot of ORR nivolumab intervention





Figure 3. (B) Funnel plot of ORR nivolumab intervention



Random-Effects Model (k = 4)

| preprint doi: https://doi.org/10.1101/2024.07.02.24309865; this version posted July 3, 2024. The copyright holder for this preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. | | | | | | | | | | |
|---|-------|--------|------|-------|-------|-------|--|--|--|--|
| Intercept | 0.534 | 0.0602 | 8.88 | <.001 | 0.416 | 0.652 | | | | |
| | | | | | | | | | | |

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

| Tau | Tau ² |] 2 | H ² | \mathbb{R}^2 | df | Q | р |
|-------|---------------------|------------|----------------|----------------|-------|--------|-------|
| 0.106 | 0.0113 (SE= 0.0118) | 79.22% | 4.811 | | 3.000 | 12.727 | 0.005 |

Figure 4. (A) Forest plot of ORR Nivolumab and Ipilimum




Figure 4. (B) Funnel plot of ORR Nivolumab and Ipilimum




Figure 5. (A) Forest plot of ORR Pembrolizumab intervent




Figure 5. (B) Funnel plot of ORR Pembrolizumab interver




Figure 6. (A) Forest plot of OS Nivolumab intervention




Figure 6. (B) Funnel plot of OS Nivolumab intervention




Figure 7. (A) Forest plot of OS Nivolumab and Ipilimumal




Figure 7. (B) Funnel plot of OS nivolumab and Ipilimuma




Figure 8. (A) Forest plot of OS Pembrolizumab intervention




Figure 8. (B) Funnel plot of OS Pembrolizumab interventi




Figure 9. (A) Forest plot of PFS Nivolumab intervention





Figure 9. (B) Funnel plot of PFS Nivolumab intervention



Tau Tau² I² H² R² df Q p

1.000

0.784

3.000

0.853

0%

0 (SE = 0.0019)

0.000

Figure 10. (A) Forest plot of OS Nivolumab and Ipilimuma




Figure 10. (B) Funnel plot of OS Nivolumab and Ipilimum




Figure 11. (A) Forest plot of PFS Pembrolizumab interven




Figure 11. (B) Funnel plot of PFS Pembrolizumab intervei